Clinical Trial

De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease

Study acronym: ABBREVIATE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Patients with heart disease are often prescribed many medications and these patients may experience drug interactions or negative drug related side effects. With newer medications and treatments available, it is not well known whether older drugs, such as beta-blockers, are still an effective and safe option for treating heart disease. Some evidence suggests beta-blockers should be continued, whereas other evidence suggests beta-blockers might cause unnecessary harm. The study hopes to determine whether continuation or discontinuation of beta-blockers will affect long term cardiovascular outcomes. The study investigators will also examine how beta-blockers continuation or discontinuation affects several quality of life measures.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-10-05; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2026-03-12
Status change: Not Yet Recruiting → Recruiting 2023-01-30
Trial Details
NCT Number NCT05081999
Lead Sponsor University of Alberta
Conditions Stable Ischemic Heart Disease, Coronary Artery Disease, Beta-blocker Therapy
Enrollment 59 participants
Start Date 2023-01-30
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-16